How to buy ADMA Biologics stock | $1.1

ADMA Biologics Inc is a biotechnology business based in the US. ADMA Biologics shares (ADMA) are listed on the NASDAQ and all prices are listed in US Dollars. ADMA Biologics employs 406 staff and has a trailing 12-month revenue of around 0.00.

ADMA Biologics stock price (NASDAQ: ADMA)

Use our graph to track the performance of ADMA stocks over time.

ADMA Biologics shares at a glance

• Key figures

Information last updated 2021-10-09.

Latest market close	$1.10
52-week range	$1.11 - $3.11
50-day moving average	$1.24
200-day moving average	$1.57
Wall St. target price	$6.60
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.69

Buy ADMA Biologics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy ADMA Biologics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

ADMA Biologics price performance over time

Historical closes compared with the close of $1.1 from 2021-10-15

1 week (2021-10-06)	-1.79%
1 month (2021-09-16)	-8.33%
3 months (2021-07-16)	-28.10%
6 months (2021-04-16)	-33.33%

1 year (2020-10-16)	-51.54%
2 years (2019-10-16)	-74.65%
3 years (2018-10-16)	5.29
5 years (2016-10-14)	6.39

ADMA Biologics financials

Revenue TTM	$58.1 million
Gross profit TTM	$-11,571,643
Return on assets TTM	-15.75%
Return on equity TTM	-78.11%
Profit margin	-126.67%
Book value	$0.85
Market capitalisation	$148.7 million

TTM: trailing 12 months

Shorting ADMA Biologics shares

There are currently 11.6 million ADMA Biologics shares held short by investors – that's known as ADMA Biologics's "short interest". This figure is 5.1% down from 12.2 million last month.

There are a few different ways that this level of interest in shorting ADMA Biologics shares can be evaluated.

ADMA Biologics's "short interest ratio" (SIR)

ADMA Biologics's "short interest ratio" (SIR) is the quantity of ADMA Biologics shares currently shorted divided by the average quantity of ADMA Biologics shares traded daily (recently around 5.8 million). ADMA Biologics's SIR currently stands at 2. In other words for every 100,000 ADMA Biologics shares traded daily on the market, roughly 2000 shares are currently held short.

However ADMA Biologics's short interest can also be evaluated against the total number of ADMA Biologics shares, or, against the total number of tradable ADMA Biologics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ADMA Biologics's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 ADMA Biologics shares in existence, roughly 90 shares are currently held short) or 0.0986% of the tradable shares (for every 100,000 tradable ADMA Biologics shares, roughly 99 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against ADMA Biologics.

Find out more about how you can short ADMA Biologics stock.

ADMA Biologics share dividends

We're not expecting ADMA Biologics to pay a dividend over the next 12 months.

ADMA Biologics share price volatility

Over the last 12 months, ADMA Biologics's shares have ranged in value from as little as $1.11 up to $3.111. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ADMA Biologics's is 1.2577. This would suggest that ADMA Biologics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

ADMA Biologics overview

ADMA Biologics, Inc. , a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States. It offers BIVIGAM, an intravenous immune globulin product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers.

Frequently asked questions

What percentage of ADMA Biologics is owned by insiders or institutions?
Currently 3.83% of ADMA Biologics shares are held by insiders and 36.21% by institutions. How many people work for ADMA Biologics?
Latest data suggests 406 work at ADMA Biologics. When does the fiscal year end for ADMA Biologics?
ADMA Biologics's fiscal year ends in December. Where is ADMA Biologics based?
ADMA Biologics's address is: 465 State Route 17, Ramsey, NJ, United States, 07446 What is ADMA Biologics's ISIN number?
ADMA Biologics's international securities identification number is: US0008991046 What is ADMA Biologics's CUSIP number?
ADMA Biologics's Committee on Uniform Securities Identification Procedures number is: 000899104